FIELD: biotechnologies.
SUBSTANCE: variational extracted antibodies 2.9D10, 2.7A4, 2.14H9 and 2.14H9-opti and their antigen-binding fragments are presented which specifically link with B7-H1 where each antibody or its antigen-binding fragment contains the set of 6 CDRs the sequences of which are presented in the description. The following is described: nucleinic acid, coding the named antibody, and the host cell producing the named antibody against B7-H1, transfected by the vector containing the named nucleinic acid. The compositions containing the effective amount of the antibody according to the present invention and pharmaceutically acceptable carrier for use in repression of B7-H1-mediated inhibition of animal T-cells are described. The following is offered: the method of repression of B7-H1-mediated inhibition of animal T-cells and the method of treatment of malignant tumour of animals connected with B7-H1, comprising injection to the animal which needs it of effective amount of the named composition.
EFFECT: invention allows to expand the arsenal of preparations against B7-H1.
22 cl, 15 dwg, 33 tbl, 19 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SPECIFIC BINDING AGENTS AGAINST B7-H1 | 2010 |
|
RU2706200C2 |
| ANTIBODIES AGAINST 5-BROMO-2'-DEOXYURIDINE AND METHODS OF USE | 2015 |
|
RU2705299C2 |
| ANTI-PD-1 ANTIBODIES | 2017 |
|
RU2752832C2 |
| ANTIBODIES TO NKG2A AND THEIR APPLICATIONS | 2007 |
|
RU2499001C2 |
| THEOPHYLLINE ANTIBODIES AND METHODS FOR THEIR APPLICATION | 2013 |
|
RU2630664C2 |
| MONOVALENT CARRIER MODULES ACROSS BLOOD-BRAIN BARRIER | 2014 |
|
RU2694659C2 |
| ANTI-IGF-1R ANTIBODY AND USE THEREOF AS AN ADDRESS VECTOR FOR CANCER TREATMENT | 2015 |
|
RU2698977C2 |
| UNIVERSAL TRANSMITTER MODULES THROUGH THE HEMATOENCEPHALITIC BARRIER | 2014 |
|
RU2799436C1 |
| ANTI-IDIOTYPIC ANTIBODIES AND METHODS RELATED TO THEM | 2017 |
|
RU2773355C2 |
| ANTIBODIES TO HER3 AND APPLICATION THEREOF | 2010 |
|
RU2560583C2 |
